GlaxoSmithKline : CECP presentation slides PDF - 505.4KB

Emma Walmsley

Chief Executive Officer

8 June 2021

Cautionary statement regarding forward-looking statements

This presentation maycontain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements bythe fact that they do not relate strictly to historical or current facts. They usewords such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'project', 'plan', 'believe', 'target' and other words and terms of similar meaning in connectionwith anydiscussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings,dividend payments and financial results.

Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update anyforward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult anyadditional disclosures that theGroup may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, manyof which relate to factors that ar e beyond the Group's control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materiallyfrom those expressed or implied in anyforward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D 'Risk factors' in the Group's Annual Report on Form 20-F for FY 2020 and any impacts of the COVID-19 pandemic. Any forward-looking statements made byor on behalf of the Group speak onlyas of the date they are made and are based upon the knowledge and information available to theDirectors on the date of this presentation.

1. number of adjusted measures are used to report the performance of our business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in our first quarter 2021 earnings release and Annual Report on Form 20-F for FY 2020.

All expectations and targets regarding future performance and the dividend should be read together with the section "Outlook,assumptions and cautionary statements" on pages 42 and 43 of our first quarter 2021 earnings release.

2

Creating significant long-term shareholder value with two new companies

2017

Innovation

Performance

Trust

Culture

Invest in R&D pipeline and improve productivity

Sharpen commercial execution, refocus portfolio, drive cost discipline

Address group structure and capital allocation

Drive culture of ambition and accountability while maintaining leadership in ESG

2022

New GSK

Update June 23 2021

New Consumer Healthcare

CMD H1 2022

3

Focused ESG approach to support delivery of long-term sustainable performance

Pricing/AccessEnvironment

Global Health & Health		Product governance
security

Inclusion & Diversity		Operating standards

4

ESG areas of focus: Pricing and access

Pricing/AccessEnvironment

Global Health & Health		Product governance
security

Inclusion & Diversity		Operating standards

5